Carbamazepine (All indications) - Medication and Pregnancy KB

Carbamazepine (All indications)

Amniotic fluid problems (polyhydramnios and/or oligohydramnios)

R analysis

id	Study	Lib. in paper	Exposition period	Study type All studies Case control excluded Only case control	Control type	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S12674 R47883	Mari (Carbamazepine), 2022	Oligohydramnios/polyhydramnios	throughout pregnancy	retrospective cohort	exposed to other treatment, sick	Adjustment: No	1.98 [0.09;44.84] ^C	2/29 0/11	2	29		ref
S9602 R34037	Aydin (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020	Amniotic fluid problems (polyhydramnios/oligohydramnios)	throughout pregnancy	retrospective cohort	exposed to other treatment, sick excluded	Adjustment: No	0.45 [0.01;25.16] ^C excluded (control group)	0/15 0/7	0	15		ref
S9603 R34047	Aydin (Carbamazepine) (Controls unexposed, sick), 2020	Amniotic fluid problems (polyhydramnios/oligohydramnios)	throughout pregnancy	retrospective cohort	unexposed, sick	Adjustment: No	1.48 [0.03;79.05] ^C	0/15 0/22	0	15		ref
					Total	2 studies	1.77 [0.15;20.65]		2	44
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; ^C: calculated odds ratio from numbers of events and effectives

Forest plot

1: Carbamazepine; 2: Carbamazepine) (Controls unexposed, sick;

Sensitivity analysis

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9602